Eli Lilly to start rolling submission for obesity drug this year
Send a link to a friend
 [October 06, 2022]
(Reuters) - Eli Lilly and Co said on
Thursday it plans to start a rolling submission to the U.S. Food and
Drug Administration (FDA) this year for approval of tirzepatide in
adults with obesity.
[to top of second column]
|
 The data it will submit will include
that from two late-stage trials, one of which is expected in April.
(Reporting by Leroy Leo in Bengaluru; editing by Uttaresh.V)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
